Roche

News

Roche builds case for TIGIT combo in untreated lung cancer

Roche's closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the evidence

News

EU approves Roche's Actemra for severe COVID-19

The European Commission has moved swiftly to grant full approval to Roche's Actemra/RoActemra as a treatment for severe COVID-19, clearing the drug within 24 hours of a recommendation from

News

AI specialist Recursion nabs multibillion-dollar Roche partn...

Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and "industrialised" drug discovery to find new neuroscience and cancer drugs.

News

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

Eli Lilly's RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer D

News

ASH abstract drop backs Roche's Polivy in first-line lymphom...

Roche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and a first look at the data suggests it is on track for approval in w

News

Roche, Blueprint's RET cancer drug Gavreto cleared in EU

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, after getting approval for Gavreto from the European Commission.

Roche builds case for TIGIT combo in untreated lung cancer

EU approves Roche's Actemra for severe COVID-19

AI specialist Recursion nabs multibillion-dollar Roche partn...

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

ASH abstract drop backs Roche's Polivy in first-line lymphom...

Roche, Blueprint's RET cancer drug Gavreto cleared in EU

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks